title: Effect of myostatin depletion on weight gain, hyperglycemia, and hepatic steatosis during five months of high-fat feeding in mice.
abstract: The marked hypermuscularity in mice with constitutive myostatin deficiency reduces fat accumulation and hyperglycemia induced by high-fat feeding, but it is unclear whether the smaller increase in muscle mass caused by postdevelopmental loss of myostatin activity has beneficial metabolic effects during high-fat feeding. We therefore examined how postdevelopmental myostatin knockout influenced effects of high-fat feeding. Male mice with ubiquitous expression of tamoxifen-inducible Cre recombinase were fed tamoxifen for 2 weeks at 4 months of age. This depleted myostatin in mice with floxed myostatin genes, but not in control mice with normal myostatin genes. Some mice were fed a high-fat diet (60% of energy) for 22 weeks, starting 2 weeks after cessation of tamoxifen feeding. Myostatin depletion increased skeletal muscle mass ∼30%. Hypermuscular mice had ∼50% less weight gain than control mice over the first 8 weeks of high-fat feeding. During the subsequent 3 months of high-fat feeding, additional weight gain was similar in control and myostatin-deficient mice. After 5 months of high-fat feeding, the mass of epididymal and retroperitoneal fat pads was similar in control and myostatin-deficient mice even though myostatin depletion reduced the weight gain attributable to the high-fat diet (mean weight with high-fat diet minus mean weight with low-fat diet: 19.9 g in control mice, 14.1 g in myostatin-deficient mice). Myostatin depletion did not alter fasting blood glucose levels after 3 or 5 months of high-fat feeding, but reduced glucose levels measured 90 min after intraperitoneal glucose injection. Myostatin depletion also attenuated hepatic steatosis and accumulation of fat in muscle tissue. We conclude that blocking myostatin signaling after maturity can attenuate some of the adverse effects of a high-fat diet.
authors.affiliation: Endocrinology and Metabolism Division, Department of Medicine, University of Rochester, Rochester, New York, United States of America.
authors.forename: Kerri
authors.initials: K
authors.lastname: Burgess
authors.forename: Tianshun
authors.initials: T
authors.lastname: Xu
authors.forename: Roger
authors.initials: R
authors.lastname: Brown
authors.forename: Bajin
authors.initials: B
authors.lastname: Han
authors.forename: Stephen
authors.initials: S
authors.lastname: Welle
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000032:analysis / Q000187:drug effects / Q000378:metabolism; D004036:Diet, Atherogenic; D004041:Dietary Fats / Q000009:adverse effects*; D005234:Fatty Liver / Q000097:blood / Q000150:complications / Q000209:etiology / Q000235:genetics*; D005947:Glucose / Q000008:administration & dosage / Q000494:pharmacology; D006943:Hyperglycemia / Q000097:blood / Q000139:chemically induced / Q000150:complications / Q000235:genetics*; D007274:Injections, Intraperitoneal; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D055435:Myostatin / Q000235:genetics* / Q000378:metabolism / Q000502:physiology; D013997:Time Factors; D015430:Weight Gain / Q000187:drug effects / Q000235:genetics* / Q000502:physiology
chemical_list: D001786:Blood Glucose; D004041:Dietary Fats; D055435:Myostatin; D005947:Glucose